Results 171 to 180 of about 8,261 (192)
Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong
Respirology, 2022 BACKGROUND AND OBJECTIVE: Few head-to-head evaluations of immune responses to different vaccines have been reported. METHODS: Surrogate virus neutralization test (sVNT) antibody levels of adults receiving either two doses of BNT162b2 (n = 366) or ...
Malik Peiris +2 more
exaly +2 more sources
Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial [PDF]
Nature Medicine, 2022 AbstractThe emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the waning of vaccine-elicited neutralizing antibodies suggests that additional coronavirus disease 2019 (COVID-19) vaccine doses may be needed for individuals who initially received CoronaVac. We evaluated the safety and immunogenicity of the recombinant
Wei Chen, Lunbiao Cui, Lihua Hou
exaly +6 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Dynamics of antibody response to CoronaVac vaccine
Journal of Medical Virology, 2022AbstractCoronaVac was the first vaccine approved in Brazil for use in healthcare workers (HCWs). However, there is limited information about it, with little long‐term evidence on post‐vaccination antibody persistence. This study evaluated the antibody response to SARS‐CoV‐2 in 1237 HCWs after the first (1D), second dose (2D), and 6 months ...
Fernanda Montenegro Carvalho de Araújo +2 more
exaly +3 more sources
Lancet, The, 2021 Background CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown to be well tolerated with a good safety profile in individuals aged 18 years and older in phase 1/2 trials, and provided a good humoral response against SARS-CoV-2.
Aykut Özkul, Alpay Azap, Ferit Kuşçu
exaly +2 more sources
MBio, 2022 CoronaVac is an inactivated SARS-CoV-2 vaccine approved by the World Health Organization (WHO). Previous studies reported increased levels of neutralizing antibodies and specific T cells 2 and 4 weeks after two doses of CoronaVac; these levels were ...
Gaspar A Pacheco +2 more
exaly +2 more sources
Safety and Immunogenicity of CoronaVac in People Living with HIV
SSRN Electronic Journal, 2021Background: People living with HIV (PLWH) may have a poor or delayed response to vaccines, mainly when CD4+ T cell counts are low. There are limited data concerning the safety and immunogenicity of COVID-19 vaccines in PLWH. Methods: This prospective controlled study evaluated the safety and immunogenicity of the SARS-CoV-2 inactivated vaccine ...
Lucas Chaves Netto +17 more
openaire +1 more source
Alopecia areata after
Miguel Aristizabal +2 more
openaire +2 more sources